My official title is Senior Director, Head of US Scientific Communications and Evidence Generation. It’s a mouthful, I know—and probably not a role most people outside of biotech have heard of. To explain how I ended up in this niche corner of the industry, I’ll rewind to the start of my career. After receiving a Pharm.D. from the University of Missouri-Kansas City, I was working as pharmacist at Target, just starting to wonder if the retail setting was a good fit for me. A former professor of mine recommended that I apply for a position in medical information at a company providing medical affairs support for a variety of pharmaceutical companies. My first thought: What in the world is medical information?

I soon found out not only what it was, but that it was perfect for me thanks to my experience in my first industry role. If a physician, patient, or pharmacist called to inquire about something, I was on the other side of that phone. I discovered that I love answering people’s questions and helping them get access to the information they are looking for.

Fast forward 12+ years and several roles later, and now I’m at ITF Therapeutics pursuing that same passion for connecting people with knowledge. My team is responsible for generating data and sharing it with the Duchenne muscular dystrophy community to support informed treatment decisions. We mine existing data sets for new meaningful information and generate new data when we identify knowledge gaps. We write articles for publication in medical journals, prepare presentations for scientific conferences, and develop materials for our medical science liaisons to use when they meet with care teams in the clinics. We also support continuing medical education through educational grants.

In our quest to gain more knowledge and share it with the community, we will continue to build upon our learnings from our first clinical trial involving 179 participants. We continue to evaluate the data that were generated to determine if there is more we can learn that may be helpful to physicians and individuals living with Duchenne as they assess their treatment options.

We are deeply grateful for the community's willingness to help advance science by participating in clinical trials. Carefully controlled studies are essential tests to determine whether a treatment is safe and effective, yet they don’t necessarily tell the whole story. Study participants are often selected based on strict eligibility criteria like age, functional status, or other factors. But in real life, patients don’t come from cookie cutters. That’s why we are now launching an observational study to collect real world evidence. With the community’s cooperation, we aim to gather data from a broader, more diverse population as they go about their daily lives. No disease stage requirements. No restrictions on other medications. Just real people who have Duchenne, living their actual lives, helping us understand the full picture.

It’s often said that data tell a story. Our mission is to tell a richer, more complete version of that story — one that reflects the complexity, diversity, and lived experiences of people with DMD. What parts of the story do you want to hear? Send us an email to let us know. We’re listening — and we’d love for you to join the conversation.

C-DUV-US-0477 06/2025